Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
GYRE THERAPEUTICS, INC. roe for the quarter ending 2026-06-30 was -26.16%, a 491.05% decline year-over-year.
GYRE THERAPEUTICS, INC. roe for the quarter ending 2026-03-31 was -15.99%, a 184.24% decline year-over-year.
GYRE THERAPEUTICS, INC. roe for the quarter ending 2025-12-31 was 11.71%, a 58.64% decline year-over-year.
GYRE THERAPEUTICS, INC. roe for the quarter ending 2025-09-30 was 9.06%, a change of 110.94% year-over-year.
GYRE THERAPEUTICS, INC. roe for fiscal 2025 was 9.32%, a 67.03% decline from fiscal 2024.
GYRE THERAPEUTICS, INC. roe for fiscal 2024 was 28.27%, a 94.77% decline from fiscal 2023.
GYRE THERAPEUTICS, INC. roe for fiscal 2023 was 540.06%, a 5223.19% increase from fiscal 2022.
GYRE THERAPEUTICS, INC. roe for fiscal 2022 was 10.15%, a change of 224.15% from fiscal 2021.